sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate
- CAS No.
- 28434-74-4
- Chemical Name:
- sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate
- Synonyms
- Bumetanide sodium;BuMetanide (sodiuM salt);PKNSNFSHDGKUOA-UHFFFAOYSA-N;Sodium 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoate;sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate;3-Aminosulfonyl-5-butylamino-4-phenoxybenzoic acid sodium salt
- CBNumber:
- CB5886861
- Molecular Formula:
- C17H19N2NaO5S
- Molecular Weight:
- 386.39793
- MDL Number:
- MOL File:
- 28434-74-4.mol
| FDA UNII | 1QC8KM52D1 |
|---|
sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate Chemical Properties, Uses, Production
Uses
Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[1][2].
in vivo
Bumetanide sodium (7.6-30.4 mg/kg; i.v.) attenuates the decrease in apparent diffusion coefficients (ADC) ratios for both cortex and striatum (by 40-67%), indicating reduced edema formation[3].
Bumetanide sodium also reduces infarct size[3].
Bumetanide sodium shows different half-lives of 21.4 min, 53.8 min and 137 min following 2 mg/kg, 8 mg/kg and 20 mg/kg intravenous injection, respectively, in rats[4].
References
[1] Lykke K, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy Behav. 2016 Jun;59: DOI:10.1016/j.yebeh.2016.03.021
[2] Ciaran Richardson, et al. Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways. J Cell Sci. 2011 Mar 1;124(Pt 5):789-800. DOI:10.1242/jcs.077230
[3] Martha E O'Donnell, et al. Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke. J Cereb Blood Flow Metab. 2004 Sep;24(9):1046-56. DOI:10.1097/01.WCB.0000130867.32663.90
[4] S H Lee, et al. Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm. 1994 Feb;22(1):1-17.6 DOI:10.1007/BF02353407
sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate Preparation Products And Raw materials
sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| DAYANG CHEM (HANGZHOU) CO.,LTD | +86-88938639 +86-17705817739 | info@dycnchem.com | China | 53589 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |
| Supplier | Advantage |
|---|---|
| DAYANG CHEM (HANGZHOU) CO.,LTD | 58 |
| TargetMol Chemicals Inc. | 58 |
View Latest Price from sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-11 | Bumetanide sodium
28434-74-4
|
10g | TargetMol Chemicals Inc. |
-
- Bumetanide sodium
28434-74-4
- $0.00
- TargetMol Chemicals Inc.
